NASDAQ
Enlivex Therapeutics Ltd. (ENLV) has a free cash flow growth of -25.54% as of Friday, May 29, 2026. This represents a 15.31% decrease compared to its 12-month average of -22.15%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.